Clinical trial · Observational
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis
Prediction of Pancreatic Cancer Prognosis Using a Multimodal Deep Learning Model Based on Intratumoral Immune Microenvironment
NCT06760234CI-TRIAL-00100359completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study describes the development and validation of a deep learning prediction model, which extracts deep learning features from preoperative enhanced CT scans and analyzes postoperative pathological specimens of pancreatic cancer patients. The aim is to predict patient prognosis and response to chemotherapy treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Interventions | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Training Cohort
- description
- Patients diagnosed with pancreatic cancer who underwent surgery and other treatments at the Second Affiliated Hospital, Zhejiang University School of Medicine
- interventionNames
- Diagnostic Test: No Interventions
- label
- Test Cohort
- description
- Patients diagnosed with pancreatic cancer who underwent surgery and other treatments at the Fourth Affiliated Hospital, Zhejiang University School of Medicine and Hangzhou Hosptial of Traditional Chinese Medicine
- interventionNames
- Diagnostic Test: No Interventions
Primary outcomes (1)
- measure
- Performance of deep learning model
- timeFrame
- Baseline treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients with pancreatic cancer, diagnosed through pathology; 2. Patients underwent surgery and received adjuvant chemotherapy after surgery. Exclusion Criteria: 1. Missing or inadequate quality of CT, 2. Incomplete clinical or pathological data. 3. Multiple primary malignancies; 4. History of malignancy.
References
Publications (1)
- DERIVEDFan Y, Du B, Pu K, Sun Y, Lv C, Hu S, Song T, Wu R, Chen Y, Tang J, Zhong Y, Bian W, Wu J, Zhang H, Ding Y, Xu H, Wu Y, Li X. Noninvasive evaluation and clinical value prediction of tumor-infiltrating neutrophil-to-T-cell ratio in pancreatic ductal adenocarcinoma. NPJ Digit Med. 2026 Jan 3;9(1):123. doi: 10.1038/s41746-025-02303-9. PMID 41484243